VERAXA BIOTECH

veraxa-biotech-logo

VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation.

#SimilarOrganizations #Financial #Website #More

VERAXA BIOTECH

Industry:
Biotechnology

Address:
Heidelberg, Baden-Wurttemberg, Germany

Country:
Germany

Website Url:
http://www.veraxa.com

Total Employee:
11+

Status:
Active

Technology used in webpage:
Amazon


Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

arcadia-science-logo

Arcadia Science

Arcadia Science is a Research and development company leveraging the biology of emerging research organisms.

cdr-life-ag-logo

CDR-Life AG

CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.

digitalhealthlondon-accelerator-logo

DigitalHealth.London Accelerator

The Accelerator aims to speed up development of digital innovations across health and care, and pioneer their adoption by the NHS.

neuway-pharma-logo

NEUWAY Pharma

NEUWAY is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases

rjh-biosciences-logo

RJH Biosciences

RJH Biosciences focus on development of transfection reagents and delivery agents for nucleic acids.

targimmune-therapeutics-logo

TargImmune Therapeutics

TargImmune Therapeutics is focused on drug development using novel targeted onco-immunotherapies.

velabs-therapeutics-logo

Velabs Therapeutics

Velabs Therapeutics is a pioneer in microfluidics-based technologies for functional screening of antibodies.

vetigenics-logo

Vetigenics

Vetigenics discovers and develops antibody-based immunotherapies to treat cancer and chronic diseases in companion animals

Acquisitions List

Date Company Article Price
2023-12-29 Synimmune GmbH Synimmune GmbH acquired by VERAXA Biotech N/A

Official Site Inspections

http://www.veraxa.com Semrush global rank: 13.71 M Semrush visits lastest month: 75

  • Host name: aacb0a264e514dd48.awsglobalaccelerator.com
  • IP address: 75.2.70.75
  • Location: Seattle United States
  • Latitude: 47.54
  • Longitude: -122.3032
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98108

Loading ...

More informations about "VERAXA Biotech"

Veraxa

At VERAXA Biotech, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics. Contact us. About us. Careers Partnering. Pipeline. โ€ฆSee details»

Our approach - Veraxa

At VERAXA, we are building an R&D organization suited to meet this future demand. A strong history in ADC development. VERAXA has established a strong position in ADC development. โ€ฆSee details»

VERAXA Biotech - Crunchbase Company Profile

Organization. VERAXA Biotech . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. VERAXA โ€ฆSee details»

Veraxa Biotech - Org Chart, Teams, Culture & Jobs - The Org

View Veraxa Biotech's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»

VERAXA Biotech and Voyager Acquisition Corp. Announce โ€ฆ

5 days ago VERAXAโ€™s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") โ€ฆSee details»

VERAXA Biotech GmbH - BIO International Convention | BIO

The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... VERAXA is an early-stage โ€ฆSee details»

Veraxa 2025 Company Profile: Valuation, Funding & Investors

When was Veraxa founded? Veraxa was founded in 2017. Where is Veraxa headquartered? Veraxa is headquartered in Heidelberg, Germany. What is the size of Veraxa? Veraxa has 39 โ€ฆSee details»

VERAXA Biotech - Funding, Financials, Valuation & Investors

Dec 29, 2023 VERAXA Biotech has acquired Synimmune GmbH on Dec 29, 2023. Acquisitions. Edit Acquisitions Section. Number of Acquisitions 1. VERAXA Biotech has acquired โ€ฆSee details»

VERAXA Biotech GmbH - Drug pipelines, Patents, Clinical trials

With this clinical asset, VERAXA strengthens its internal cancer pipeline of innovative antibodies and antibody-drug conjugates (ADCs). AML, characterized by its prevalence in individuals โ€ฆSee details»

Superior cancer therapeutics using transformative innovations

Building a unique pipeline. With a strong foundation in ADCs and our lead program in clinical studies in AMLSee details»

Veraxa Biotech AG โ€“ Swiss Biotech

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members, the association works to secure favorable framework โ€ฆSee details»

VERAXA and Voyager to Create Combined Business for Advancing โ€ฆ

5 days ago โ€œVERAXA is committed to developing and delivering the next wave of safe and highly efficacious cancer therapies. Our platform technologies can be applied to empower multiple โ€ฆSee details»

Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC โ€ฆ

5 days ago Swiss biotech investor Xlife Sciences AG said on Wednesday its portfolio company Veraxa Biotech AG would list on U.S. exchange Nasdaq in a $1.64 billion merger deal with a โ€ฆSee details»

Veraxa to go public in $1.6bn SPAC deal with Voyager

4 days ago Veraxa said that it will be pursuing multiple strategic partnerships and licensing opportunities in 2025 and 2026. Veraxaโ€™s CEO Christoph Antz said the companyโ€™s platform is โ€ฆSee details»

VERAXA Biotech | The Pharmaletter

4 days ago In April 2025, VERAXA announced a definitive business combination agreement with Voyager Acquisition Corp., a special purpose acquisition company (SPAC), to become a โ€ฆSee details»

VERAXA Biotech AG and Voyager Acquisition Corp.

5 days ago Summary. On April 23, 2025, VERAXA Biotech AG and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the โ€ฆSee details»

Voyager Acquisition Corp. and VERAXA Biotech Announce โ€ฆ

5 days ago The combination will result in VERAXA becoming a publicly traded company on Nasdaq under the ticker symbol โ€œVERXโ€, with a pre-money equity valuation of $1.3 billion and โ€ฆSee details»

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

5 days ago Zurich-based start-up Veraxa Biotech has reached a deal to merge with special purpose acquisition company (SPAC) Voyager, gaining a listing on the Nasdaq that will give it โ€ฆSee details»

Veraxa Biotech Set to Go Public with $1.6 Billion SPAC Merger: A โ€ฆ

4 days ago Veraxa aims to leverage artificial intelligence to reduce side effects and maximize market impact in cancer treatment. Overview of the SPAC Merger and Financial Implications. โ€ฆSee details»

Veraxa

5 days ago ZURICH, SWITZERLAND, and BROOKLYN, NEW YORK, USA, April 23, 2025 --VERAXA Biotech AG(โ€œVERAXAโ€ or the โ€œCompanyโ€), an emerging leader in designing novel โ€ฆSee details»

linkstock.net © 2022. All rights reserved